Zimmer Biomet Sees Unusually Large Options Volume (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) saw unusually large options trading on Friday. Stock investors bought 2,270 call options on the company. This represents an increase of approximately 534% compared to the average volume of 358 call options.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. dropped their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research report on Wednesday, April 29th. Robert W. Baird set a $92.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Barclays lowered their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. BMO Capital Markets started coverage on Zimmer Biomet in a research note on Wednesday. They set a “market perform” rating and a $95.00 target price for the company. Finally, Truist Financial reaffirmed a “hold” rating and issued a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $102.33.

Insider Buying and Selling

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.28% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ZBH. DV Equities LLC acquired a new position in Zimmer Biomet during the 4th quarter worth about $25,000. Monetary Solutions Ltd acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $30,000. Gen Wealth Partners Inc bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $31,000. Flagship Harbor Advisors LLC bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $32,000. Finally, Elevation Wealth Partners LLC lifted its stake in shares of Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 229 shares during the period. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Up 2.2%

Shares of NYSE:ZBH traded up $2.00 during midday trading on Friday, hitting $91.23. 236,206 shares of the stock were exchanged, compared to its average volume of 2,283,044. The stock has a market capitalization of $17.65 billion, a price-to-earnings ratio of 23.64, a P/E/G ratio of 2.58 and a beta of 0.46. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The business’s 50-day moving average price is $86.03 and its 200 day moving average price is $89.75. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same period in the previous year, the firm posted $1.81 EPS. The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Analysts predict that Zimmer Biomet will post 8.48 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is currently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.